|
1. Biologie
|
|
|
|
|
The Elephant (not) in the Cancer Ward [The Mermaid's Tale]
|
|
|
|
|
|
Elephants
live long lives relative to other diseases that essentially have little
if anything to do with cancer. One can think of heart disease,
dementia, stroke, kidney failure, liver disease, neuromuscular and joint
disease, and waning immune systems. Are these traits all due to having
more TP53? That seems unlikely.
|
|
|
|
|
|
|
3. Prévention
|
|
|
New NIH breast cancer research to focus on prevention [NIH]
|
|
|
|
|
|
A
new phase of the Breast Cancer and the Environment Research Program
(BCERP), focused on prevention, is being launched at the National
Institutes of Health. Grant-funded researchers will now work across
scientific disciplines, involve new racially and ethnically diverse
communities, and expand the study of risk factors that precede breast
cancer, such as breast density.
|
|
|
|
|
|
|
4.5 Dép., diag. & prono. - Colorectal
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
Yes, Early Breast Cancer Detection Does Matter, New Study Finds [Forbes]
|
|
|
|
|
|
So
if mammography in 2015 is not good enough, the reasonable ways forward
are either to make it better or more consistent in quality (at the
population level), or to develop an alternative, superior screening tool
for women at risk of suffering and death from breast cancer – and that
would include most middle-aged women, some younger at high-risk, and
many older women.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
FDA expands approved use of Opdivo in advanced lung cancer [FDA]
|
|
|
|
|
|
The
safety and effectiveness of Opdivo for this use was demonstrated in an
international, open-label, randomized study of 582 participants with
advanced NSCLC whose disease progressed during or after treatment with
platinum-based chemotherapy and appropriate biologic therapy.
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
6.1 Observation
|
|
|
|
6.3 Associations
|
|
|
|
|
|
|
6.4 Médico-éco
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.9 Controverses
|
|
|